Sign in

    Chris Yu

    Research Analyst at Morgan Stanley

    Chris Yu is an Equity Analyst at Morgan Stanley & Co. LLC, specializing in equity research since joining the firm in 2022. He covers select publicly listed companies, providing fundamental analysis and investment recommendations, though specific coverage companies and precise performance metrics such as TipRanks rankings or return percentages are not publicly documented. Dr. Yu began his professional career after earning a doctorate from Harvard University in 2012 and has rapidly established a reputation in financial analysis through contributions in quantitative equity research. He holds advanced academic credentials and likely maintains appropriate securities licenses for his analyst role, though specific FINRA registrations are not confirmed in public sources.

    Chris Yu's questions to VERTEX PHARMACEUTICALS INC / MA (VRTX) leadership

    Chris Yu's questions to VERTEX PHARMACEUTICALS INC / MA (VRTX) leadership • Q3 2024

    Question

    Chris Yu, on for Terence Flynn at Morgan Stanley, asked about the pricing strategy for suzetrigine, seeking insight into the key inputs Vertex is considering for its pricing decisions.

    Answer

    Chief Operating Officer Stuart Arbuckle stated that suzetrigine's price will be determined by the level of clinical benefit it provides and the significant unmet need it addresses for both individual patients and society. The final pricing decision will be made closer to the approval date.

    Ask Fintool Equity Research AI